BrainSense™ technology
The only complete sensing-enabled DBS system, now with the world’s first closed-loop feature for Parkinson's disease.
You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
We do not review or control the content on non-Medtronic sites, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
The only complete sensing-enabled DBS system, now with the world’s first closed-loop feature for Parkinson's disease.
The Percept™ family with BrainSense™ technology* is the only complete sensing-enabled DBS system offering insights into a patient’s condition inside and outside of the clinic throughout the patient journey.
The BrainSense™ Electrode Identifier feature guides you to the sensing “sweet spot” on the lead, providing a starting point for DBS programming and identification of initial contacts for stimulation delivery.
aDBS uses BrainSense™ technology to automatically adjust therapeutic stimulation to effectively control motor symptom control throughout the day and night.
©2025 TIME USA LLC. All rights reserved. Used under license.
BrainSense aDBS How it Works video - (00:55)
BrainSense aDBS How it Works video
More information (see more)
Less information (see less)
Clinical effectiveness. Patient preference. Long term safety.
Extra >1 hour of good “On” time and 55% reduction of “Off” time†
98% of patients preferred aDBS over cDBS‡,§
aDBS is as safe as cDBS‡,||
Webinar- The ADAPT-PD Trial & Everyday Practice with BrainSense™ Adaptive DBS for Parkinson's - (64:01)
Webinar- The ADAPT-PD Trial & Everyday Practice with BrainSense™ Adaptive DBS for Parkinson's
More information (see more)
Less information (see less)
Access on-demand resources — videos, webinars, and more — to deepen your knowledge and uncover the innovations transforming movement disorder care.
Call UK Technical Services & Mobility Support
+44 1923 201 805
The material on this website should not be considered the exclusive source of information, it does not replace or supersede information contained in the device manual(s).
Please note that the intended use of a product may vary depending on geographical approvals.
See the device manual(s) for detailed information regarding the intended use, the (implant) procedure, indications, contraindications, warnings, precautions, and potential adverse events.
For a MRI compatible device(s), consult the MRI information in the device manual(s) before performing a MRI.
If a device is eligible for eIFU usage, instructions for use can be found at Medtronic’s website manuals.medtronic.com.
Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.
Medtronic products placed on European markets comply with EU and UK legislation (if applicable) on medical devices.
For any further information, contact your local Medtronic representative.
Bronte-Stewart HM, Beudel M, Ostrem JL, et al. Long-Term Personalized Adaptive Deep Brain Stimulation in Parkinson Disease: A Nonrandomized Clinical Trial. JAMA Neurol. Published online September 22, 2025. doi:10.1001/jamaneurol.2025.2781
The sensing feature of the Percept™ PC system and Percept™ RC system is intended for use in patients receiving DBS where chronically recorded bioelectric data may provide useful, objective information regarding patient clinical status. Signal may not be present or measurable in all patients.
Improved motor symptom control results were based on post hoc analysis averaging overall patients aDBS on time results compared to cDBS. Results prestend for dual threshold aDBS. N=40. Based on results from an open-label comparison.
Data from 45 patients who were previously stable on cDBS (primary cohort).
Over traditional DBS (cDBS) after using 30 days.
The safety profile observed for aDBS is consistent with the safety profile for cDBS.